Physician profile
Hui Chen
NPI 1710237185
$5,479.88
in general payments reported to CMS, 2019-2025
18 companies · $3,168 in 2025
The $3,168 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $20.18 · 2022: $397 · 2023: $134 · 2024: $1,547 · 2025: $3,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,125 · Food and Beverage: $625 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,125.00 |
| Food and Beverage | $625.41 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,238.02 | 2022-2025 | Imfinzi |
| Lilly USA, LLC | $308.52 | 2019-2022 | |
| Celgene Corporation | $260.82 | 2022-2025 | Pomalyst, Reblozyl |
| Pfizer INC. | $114.27 | 2019-2025 | |
| Seagen INC. | $99.95 | 2019 | |
| Aveo Pharmaceuticals, INC. | $99.00 | 2024 | |
| Merck Sharp & Dohme LLC | $76.50 | 2024 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $53.99 | 2024-2025 | Erleada, Akeega |
| Novartis Pharmaceuticals Corporation | $47.69 | 2024-2025 | |
| Daiichi Sankyo INC. | $45.78 | 2024 | Injectafer |
| Sobi, INC | $26.95 | 2025 | |
| Beigene USA, INC. | $24.70 | 2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $21.63 | 2023 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $16.38 | 2025 | Onivyde |
| Cumberland Pharmaceuticals, INC. | $15.72 | 2024 | Sancuso |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $15.46 | 2024 | Cosela |
| Tersera Therapeutics LLC | $14.50 | 2025 | Xermelo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.